Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Date:7/7/2009

with Zometa.

About Denosumab and Amgen's Research in Bone Biology

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone). With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials testing the drug for bone loss and destruction associated with cancer treatment-induced bone loss in breast and prostate cancers, for the prevention of skeletal related events due to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential to delay bone metastases in prostate cancer.

Bone Metastases: Impact and Prevalence

Bone metastases, cancer cells that separate from tumors and migrate to bone tissue where they settle and grow, occur in more than 1.5 million people worldwide.(1) With improvements in cancer care, including earlier diagnosis and new treatment options, leading to increases in survival rates(2), the number of patients developing metastatic disease secondary to a primary cancer is increasing. Bone metastases are a significant problem for patients with certain types of advanced cancer, with incidence rates of nearly 100 percent in myeloma patients and as high as 75 percent in breast and prostate cancer patients.

With bone metastases the growing cancer cells weaken and destroy the bone around the tumor. The damage the tumor has caused to the bone can result in a number of serious
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
4. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
7. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 Amgen (NASDAQ: ... two pivotal Phase 3, global, randomized, placebo-controlled trials ... treatment of secondary hyperparathyroidism (SHPT) in patients with ... met the primary endpoint, demonstrating that a greater ... achieved a greater than 30 percent reduction in ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... 2015 Zimmer Holdings, Inc. (NYSE and SIX: ... with buyers to divest in the United ... assets, Biomet Discovery® Elbow System assets and Cobalt™ bone ... Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... constructively with the Bureau of Competition Staff of the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... Reportlinker.com announces that a new market research ... Triple Analysis: Lung Cancer, Lymphoma ... This triple analysis ... both Lung Cancer and Lymphoma and by ...
... 23, 2011 Applied Medical today announced that it ... Covidien) on May 17, 2011 in the U.S. District ... a recently issued Applied Medical trocar seal patent by ... Action No. CV 11-4203 VBF (AJWx). The patent is ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... On Thursday, May 14, the Mesothelioma ... Dr. Evan Alley both of the University of ... series. The interview was part of the series ... Drs. Simone and Alley were interviewed by the ... they discussed the mesothelioma program at the University ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The iconic ... Jones, will be hosting a new segment on Medical ... aspects of medical malpractice in the health care field. ... 2014 thousands of medical malpractice suits were filed, roughly ... 50% were settled out of court, while the remaining ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2
... Drought Tolerance, DES MOINES, Iowa, Feb. 4 ... today for a three-day project review,meeting focused on ... DD ) business Pioneer-Hi-Bred, the intent of ... and private organizations in order to,help increase farm ...
... The Beryl Companies announced today the,appointment ... president of,marketing communications. In this role, she ... branding initiatives, working closely,with sales, customer relations ... extensive background in marketing communications,research and operations ...
... by more than 78% , , MONDAY, Feb. 4 (HealthDay News) ... down, a new study shows it may also ease the ... simple sugar-and-water solution will also ease parents, fears and boost ... parents to get their children vaccinated," said study author Linda ...
... - Advocacy Group Urges Russian President Vladimir Putin to Adopt a ... ... The Movement Against Cancer, a cancer,patient advocacy group in Russia, ... inadequate access for cancer,patients in Russia to innovative and effective treatments, ...
... Calif., Feb. 4 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... announced that Jerry McMahon, Ph.D., chairman and CEO,will ... Investor Conference 2008 on,Monday, February 11, at 11:45 ... Dr. McMahon will provide a corporate overview, ...
... Medco Health,Solutions, Inc. (NYSE: MHS ) plans ... a press release before the market opens,on Tuesday, Feb. ... a conference call to review,the financial results, outlook and ... the live conference call via telephone:, Dial in: ...
Cached Medicine News:Health News:DuPont Hosts Meeting of Leading Plant Scientists to Improve World Agricultural Productivity 2Health News:Sugar Water Eases Pain of Infant Vaccinations 2Health News:Sugar Water Eases Pain of Infant Vaccinations 3Health News:Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia 2Health News:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Health News:Medco Announces Date for Fourth-Quarter and Full-Year 2007 Financial Results 2
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... The HemoPoint H2 Hemoglobin Measurement ... determination of hemoglobin in arterial, venous, ... infants, and children in a professional ... number 3010-100 is indicated for use ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... Self-Sampling: ,Place the ImmunoDip into ... precise amount of sample needed for,an accurate ... run to completion,in 3 minutes. , ... color bands remain stable,for at least eight ...
Medicine Products: